Glaucoma Management During Pregnancy and Lactation

Amrit Mandal,1 Anwara Mammel,1 Harman Preet Kaur,2 Manav Deep Singh,1 Shreya Gujral,1 Anuj Kumar1

1Department of Ophthalmology, Atal Bihari Vajpayee Institute of Medical Sciences and Dr. R. M. L. Hospital, New Delhi, India.
2Department of Gynaecology and Obstetrics, Palika Maternity Hospital, Lodhi Colony, New Delhi, India.

Glaucoma is a chronic, progressive disease of advancing age which is relatively uncommon in childbearing age. However, with increasing professionalism among women, late pregnancies are becoming more common. This combined with early onset of ageing diseases in India, including glaucoma, more and more cases of glaucoma are being seen among pregnant women. Management of glaucoma in and around pregnancy is a unique challenge of balancing the risk of vision loss to the mother against the potential harm to the foetus or newborn. During pregnancy, there is physiological reduction in intraocular pressure (IOP). However, some women with pre-existing glaucoma have elevated IOP requiring enhanced medical treatment. The only anti-glaucoma medication categorized in Category B is brimonidine, all others being in Category C. Laser trabeculoplasty is an alternative treatment that can be performed in all trimesters. In selected pregnant glaucoma patients with medically uncontrolled and progressive glaucoma, surgery with caution may lead to good outcomes for the patient with no additional risk for the foetus, especially in second trimester. Beta blockers and carbonic anhydrase inhibitors are preferred for use during lactation when brimonidine is an absolute contraindication due to its ability to cross blood brain barrier. Possible options for glaucoma management and their risks should be discussed with pregnant and lactating patients and optimum treatment given so as to prevent any further deterioration in progressive vision loss and quality of life.

Abstract

Glaucoma, primarily a disease of the older population, may affect women of childbearing age. Although Quigley and Broman in 2006 estimated that by 2020 women will comprise 59 % of all glaucoma patients (55% POAG and 70 % PACG), studies on Indian population speak differently.1 A population based study on Indian Singaporeans in 2013 reported incidence of glaucoma to be 2.58% among males and 2.01% among females.2 Similarly, Paul et al, in 2016, in a population survey, found that among patients ‘of glaucoma - 53.42 to 55.31% were males.3 In pregnant women, incidence of glaucoma is increasing due to the growing tendency to start families late and with advances in medical and obstetric care ensuring safe birth in older and career conscious women. With increasing awareness and due to availability of new diagnostic techniques, glaucoma is being detected early as well. Most of these women are ‘un-aware’ of the possible risk of birth defects associated with anti-glaucoma drugs leading to reduced adherence during pregnancy. Although intraocular pressure (IOP) is known to reduce, physiologically during pregnancy, in some cases it can increase, necessitating enhanced medical, laser, or surgical intervention.4-6 Treating glaucoma during the patient’s pregnancy and lactation requires weighing the potential benefits of therapy and the visual goals of the mother against the risks of treatment to the foetus or infant. Due to ethical and legal constraints on conducting clinical trials in these groups, there is paucity of literature and there are no evidence based guidelines for managing this clinical situation. In this review, we aim to collect the array of available data from observational studies and case reports to provide the reader with guidance and context for the safety of glaucoma management during pregnancy and lactation.

Keywords: Pregnancy, Lactation, Glaucoma, Glaucoma In Pregnancy.

Introduction

Glaucoma is a chronic, progressive disease of advancing age which is relatively uncommon in childbearing age. However, with increasing professionalism among women, late pregnancies are becoming more common. This combined with early onset of ageing diseases in India, including glaucoma, more and more cases of glaucoma are being seen among pregnant women. Management of glaucoma in and around pregnancy is a unique challenge of balancing the risk of vision loss to the mother against the potential harm to the foetus or newborn. During pregnancy, there is physiological reduction in intraocular pressure (IOP). However, some women with pre-existing glaucoma have elevated IOP requiring enhanced medical treatment. The only anti-glaucoma medication categorized in Category B is brimonidine, all others being in Category C. Laser trabeculoplasty is an alternative treatment that can be performed in all trimesters. In selected pregnant glaucoma patients with medically uncontrolled and progressive glaucoma, surgery with caution may lead to good outcomes for the patient with no additional risk for the foetus, especially in second trimester. Beta blockers and carbonic anhydrase inhibitors are preferred for use during lactation when brimonidine is an absolute contraindication due to its ability to cross blood brain barrier. Possible options for glaucoma management and their risks should be discussed with pregnant and lactating patients and optimum treatment given so as to prevent any further deterioration in progressive vision loss and quality of life.

Medical Management

The FDA has classified drugs according to their safety in pregnancy as under:7

- Category A- deemed safe
- Category B- possibly safe to use in pregnancy
- Category C - adverse effects reported in animal studies
- Category D- definite risks but possible benefits
- Category X- drugs with known risks to the foetus that cannot be outweighed by possible benefits

Prostaglandin Analogues

Prostaglandin analogues such as latanoprost, bimatoprost, travoprost and tafluprost reduce the IOP by increasing the uveoscleral outflow. They are classified as category C drugs. Being oxytocic, they can increase the uterine tone and stimulate uterine contractions producing premature labor.5-11 Latanoprost exposure has not been associated with any increased risk of congenital malformations or spontaneous abortion during pregnancy but low birth weight was found to be common in these babies than the non-exposed ones.9 There are no published data regarding the use of bimatoprost, travoprost or tafluprost in pregnancy. Latanoprostene bunod 0.24% (Vyzulta) is a new prostaglandin analogue with no human data. However in rabbits, fetal toxicity was noted starting at intravitreal dose of over 0.28 times the clinical dose. It is classified as category D drug.12

Beta Blockers

Oral beta blockers are categorized as class C medications in pregnancy. No categorization is available for topical medications. Topical beta blockers like timolol, betaxolol, carteolol, levobunol and metipranolol decrease the IOP by
reducing the aqeous humour production. A population based study of 244 pregnant women on topical antiglaucoma medications showed that the risk of low birth weight infant was higher in mothers using anti-glaucoma medication other than beta blockers.13 Topical beta blockers can be considered as the first line drugs in the medical treatment of glaucoma in pregnant women. Systemic use of beta blockers close to delivery may results in foetal and neonatal bradarythmia, hypotension and hypoglycaemia.14,15 Respiratory distress and apnoea have been reported following in-utero exposure. Neonatal symptoms due to the beta blockers are usually mild and resolve within 48 hours. However, none of the side effects have been reported with low dose timolol 0.1% in gel formulation. In contrast to adults, this group of drugs is more effective than PG analogues among children.

**Alpha adrenergic agonists**

Brimonidine is the only ocular hypotensive drug which is classified as category B medication by FDA and is, thus, considered safe in pregnancy. However, it causes central nervous system depression and apnoea in the newborn as it crosses the blood brain barrier and possibly secreted into the breast milk thereby posing substantial risk to the neonate.16,17 It is contraindicated in infants and children upto 10 years of age because of the propensity of systemic side effects.

**Carbonic anhydrase inhibitors**

Dorzolamide and brinzolamide are classified as category C drugs. There were malformations of the vertebral bodies in rabbits exposed to dorzolamide during pregnancy, suggesting that brinzolamide may be a better alternative.18 No controlled reports of brinzolamide or dorzolamide exist in human pregnancy. Studies showed that oral carbonic anhydrase inhibitor acetazolamide is associated with sacrococcygeal teratoma and renal tubular acidosis in neonates.19,20 They resulted in forelimb anomalies in rats suggesting a possible teratogenic effect.20,21 Oral acetazolamide is better tolerated in children than adults, however, long term usage can cause growth retardation.22 While in first trimester, oral CAIs are absolutely contraindicated, in second and third trimester, they can be used with caution after assessing the risk versus benefit ratio, for IOP not amenable to treatment with topical medications.

**Rho kinase Inhibitors**

Netarsudil 0.2% is a new category of anti-glaucoma medication. This drug has not been classified yet because of lack of clinical studies. In rabbits, 214 fold the human clinical dose did not cause any adverse events to the foetus. There are no human studies.

**Parasympathomimetics**

These medications are categorized as group C by FDA for use in pregnancy. Although pilocarpine and carbachol have demonstrated teratogenic and adverse foetal effects in animals, the use of systemic cholinergic drugs found no association between their use during the first four months of gestation and congenital abnormalities.241 When given near the term, they have been associated with neonatal hyperthermia, restlessness, seizures, diaphoresis and mimicked the signs of meningitis.25,26

**Osmotic Agents**

The osmotic agents viz. mannitol and glycerol have been assigned category C. There are no animal or human studies in pregnancy.

**Preference of drugs according to the stage of pregnancy**

**First trimester**

Brimonidine, a category B drug, may be the safest option for the first trimester. Other antiglaucoma medications such as beta blocker, carbonic anhydrase inhibitors and prostaglandins should be avoided in the first trimester to reduce potential teratogenic effects or premature abortion.

**Second trimester**

Brimonidine can be given and beta blockers can be used with regular foetal heart rate and growth monitoring. Brinzolamide, PGAs and pilocarpine may also be used as second line drug with due cation and monitoring.

**Third trimester**

Brimonidine, beta blocker or topical carbonic anhydrase can be used with caution. Towards late in third trimester, brimonidine should be discontinued because it can induce central nervous system depression in newborn. Topical carbonic anhydrase inhibitors may be optimal in this period. Prostaglandins should be avoided because of the risk of inducing uterine contraction and labour.

**Post partum**

Brimonidine is contraindicated for lactating mothers. Beta blockers and carbonic anhydrase inhibitors are certified by the American Academy of Paediatrics as safe during nursing.

**Role Of Lasers**

Laser trabeculoplasty may be a reasonable alternative management if allowed by the morphology of the angle. Selective laser trabeculoplasty (SLT) and argon laser trabeculoplasty (ALT) are equally safe and effective. These can be used in all trimesters. However, benefits of Laser trabeculoplasty are short lived in the form of IOP control. But, they will generally be efficacious until the end of pregnancy and lactation.

Selective laser trabeculoplasty (SLT): The intracellular micro-disruptions caused by this technique are confined to the targeted cells. The laser pulses are so temporary that heat caused within the targeted cells does not spread to the surrounding tissue.28 As a result, this procedure can be repeated as well, if required. If available and anatomically feasible, this can probably become the most accepted first line treatment during pregnancy and lactation.

**Surgical Management**

In any female with advanced glaucoma and elevated pressures despite multiple medications, serious consideration should be given to surgery before conception because pre-existin glaucoma can worsen despite medical and laser treatment. During pregnancy, surgery is best avoided as it has potential risks for both the mother and foetus. The challenges include
problems with anaesthesia, positioning for surgery, potential risk with antimetabolites and concerns with the management of postoperative complications. Altered maternal physiology predisposes pregnant women to hypoxia, hypercapnia, and systemic hypotension, which exposes both mother and foetus to the risk of anaesthesia, more so general anaesthesia. Most local anaesthetics are not teratogenic in humans and are considered relatively safe for use during pregnancy. According to FDA’s classification, etidocaine, lidocaine, and prilocaine are categorized in group B while bupivacaine and mepivacaine are placed in group C as they can induce foetal bradycardia. Placental transfer of anaesthetic agents such as narcotics, paralyzing agents, and inhalational agents can cause foetal cardiovascular and central nervous system depression. Reports have shown an increased incidence of low birth weight and neural tube defects with exposure to general anaesthesia in the first trimester. Subconjunctival and anterior sub-tenon anaesthesia combined with a topical anaesthesia for glaucoma surgery may be well tolerated and may allow a less systemic absorption of the medication than a retro bulbar/peri-bulbar anaesthesia. It is desirable to defer surgery until the second trimester of pregnancy to reduce the foetuses’ exposure to the minimum to these potentially teratogenic anaesthetic agents. The supine position in the second and third trimesters of gestation can induce profound systemic hypotension due to aortic and vena caval compression by the conceived uterus. Intraoperative foetal heart rate monitoring using non stress test (NST) could also be done to prevent foetal complications during surgery. As chances of gastroesophageal reflux are high, full stomach should be avoided during surgery under any kind of anaesthesia. There is increased risk of thromboembolic disease during pregnancy. Thus, pregnant patients undergoing longer procedures, like tube surgeries, may benefit from graduated compression stockings or pneumatic compression devices. Filtration surgery may be at relatively higher risk of failure because of young age, physiological changes during pregnancy and contraindicated antimetabolite usage (both mitomycin C and 5-fluorouracil, are in category X and contraindicated in pregnancy). Using biodegradable, implantable, porous collagen matrix (Ologen) sub-conjunctivally could be an option to modulate wound healing. The presence of tissue oedema, possibly due to hormonal changes, makes scleral and conjunctival suturing difficult. This is likely to affect postoperative tissue healing and bleb morphology. Releasable sutures are preferable for controlled filtration and IOP management in the postoperative period. Valved glaucoma drainage devices seem to be a reasonable alternative to treat refractory glaucoma during pregnancy. Newer minimally invasive glaucoma surgery (MIGS) procedures may also become safer and effective alternative for pregnant patients in future.

### Post-Operative Precautions
Topical antibiotics should be used judiciously during postoperative period. Cefazolin and Penicillin group of drugs fall in category B of US-FDA and are considered safe in pregnancy. Given the absence of clear complications associated with topical steroids, they can be used in pregnant women. Prednisolone and methylprednisolone cross the placenta less than betamethasone and dexamethasone and may have less effect on the foetus. Homatropine hydrochloride 2% eye drops can be used as its ophthalmic dosage is less likely to affect the foetus. Atropine should be avoided as it can cause foetal bradycardia. All topical medications, including ocular hypertensives, should be prescribed with punctal occlusion and eyelid closure to reduce systemic absorption. Patients should be advised to avoid blinking immediately after the instillation of eye drops as blinking can activate the lacrimal pump action and increase systemic absorption.

### Summary
To choose to start families later in life is now commonplace for women. Thus, the frequency of glaucoma around pregnancy is on the rise. Physicians should initiate discussions with all women of child-bearing age requiring medical treatment for glaucoma, as women may not always inform their ophthalmologist about their desire to become pregnant. Careful consideration of foetal health in the management of glaucoma during pregnancy and lactation is best done as a part of a multidisciplinary team including obstetrics and neonatology. When medication is necessary, selection of safest agent, using minimal effective dosage and duration and steps to minimize systemic absorption should be employed. Laser trabecuoplasty appears to be safe and effective for lowering the IOP during pregnancy and is a good alternative or adjunct to medications. Surgery, if required, is best performed before planning family. However, those who require surgical management, during pregnancy, second trimester is the safest. The patient may be involved in the therapeutic decision-making process and it is important to emphasize the lack of definitive studies. Acknowledgements: Dr. Kishore Govekar, Professor and HOD Department of Ophthalmology for his valuable guidance.

### References
1. Quegley HA and Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90(3):262-267.
2. Narayanaswamy A, Baskaran M, Zheng Y, Lavanya R, Wu R, Wong WL, Saw SM, Chen CY, Wong TY and Aung T. The Prevalence and Types of Glaucoma in an Urban Indian Population: The Singapore Indian Eye Study. Invest Ophthalmol Vis Sc 2013;54:4621-4627.
3. Paul C, Sengupta S, Choudhury S, Banerjee S and Sleath BL. Pravelance of Glaucoma in Eastern India: The Hoogly River Glaucoma Study. Ind J Ophthalmol 2016;64(8):578-583.
4. Phillips CI, Gore SM. Ocular hypotensive effect of late pregnancy with and without high blood pressure. Br J Ophthalmol 1985; 69:117-9.
5. Becker B, Friedenwald JS. Clinical aqueous outflow. AMA Arch Ophthalmol 1953; 50:557-71.
6. Paterson GD, Miller SJ. Hormonal influence in simple glaucoma: A preliminary report. Br J Ophthalmol 1963; 47:129-37.
7. FDA Pregnancy Categories. January 9, 2019. http://www.drugs.com/pregnancy-categories.html. Accessed June 2, 2020.
8. Russo A, Riva I, Pizzolante T, Noto F, Quanrant L. Latanoprost...
ophthalmic solution in the treatment of open angle glaucoma or raised intraocular pressure: a review. Clin Ophthalmol 2008; 2(4):897-905.

9. Denis P, Covert D, Realini A. Travoprost in the management of open-angle glaucoma and ocular hypertension. Clin Ophthalmol 2007; 1(1):11-24.

10. De Santis M, Luccese A, Carducci B, Cavaliere AF, De Santis L, Merola A, Straface G, et al. Latanoprost exposure in pregnancy. Am J Ophthalmol 2004; 138(2):305-6.

11. Apte F, Chiquet C, Romanet JP. Intraocular pressure-lowering combination therapies with prostaglandin analogues. Drugs 2012; 72(10):1355-71.

12. Bausch & Lomb. Manufacturer’s information: Vyzulta. 2017. Available at:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207795Orig1s000lbl.pdf; Accessed May 29, 2020.

13. Ho JD, Hu CC, Lin HC. Antiglaucoma medications during pregnancy and the risk of low birth weight: A population-based study. Br J Ophthalmol 2009; 93:1283-6.

14. Razeghinejad MR, Nowroozzadeh MH. Anti-glaucoma medication exposure in pregnancy: an observational study and literature review. Clin Exp Optom 2010; 93(6):458-65.

15. Salim S. Glaucoma in pregnancy. Curr Opin Ophthalmol 2014; 25(2):93-7.

16. Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006; 2(4):337-46.

17. Rahman MQ, Ramaesh K, Montgomery DM. Brimonidine for glaucoma. Expert Opin Drugs Saf 2010; 9(3):11-15.

18. Ozawa H, Azuma E, Shindo K, Higashigawa M, Mukouhara R, Komada Y. Transient renal tubular acidosis in a neonate following transplacental acetazolamide. Eur J Pediatr 2001; 160(5):321-22.

19. Worsham F Jr, Beckman EN, Mitchell EH. Sacrococcygeal teratoma in a neonate association with maternal use of acetazolamide: an electron microscopic study. Teratology 1985; 31(2):253-63.

20. Holmes LB, Kawanishi H, Munoz A. Acetazolamide: maternal toxicity, pattern of malformations, and litter effect. Teratology 1988; 37(4):335-42.

21. Weaver TE, Scott WJ Jr. Acetazolamide teratogenesis: interaction of maternal metabolic and respiratory acidosis in the induction of ectrodactyly in C57B/6J mice. Teratology 1984; 30(2):195-202.

22. Portellos M, Buckley EG, Freedman SF. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. J AAPOS. 1998; 2:43-7.

23. Koonef KS, Zimmerman TJ. Antiglaucoma therapy during pregnancy – Part II. Ann Ophthalmol 1988; 20:208-11.

24. Samples JR, Meyer SM. Use of ophthalmic medications in pregnant and nursing women. Am J Ophthalmol. 1988; 106:616-23.

25. Rick E, Bendel MS. Principles and complications of medical therapy of glaucoma. In: Zimmerman TJ, Koonef KS, editors. Clinical Pathways in Glaucoma. New York: Thieme; 2001. pp. 427-55.

26. Committee on Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human breast milk. (cited April 2, 2018) (Accessed June 3, 2020); 2001.

27. Latina MA, Park C. Selective targeting of trabecular meshwork cells: in vitro studies of pulsed and CW laser interactions. Exp Eye Res. 1995; 60:359-371.

28. Best UP, Domack H, Schmidt V. Pressure Reduction After Selective Laser Trabeculoplasty With Two Different Laser Systems and After Argon Laser Trabeculoplasty—A Controlled Prospective Clinical Trial on 284 Eyes. Klin Monbl Augenheilkd. 2007 Mar; 224(3):173-9.

29. Razeghinejad MR, Masoumpour M, Eghbal MH, Myers JS, Moster MR. Glaucoma surgery in pregnancy: A case series and literature review. Iran J Med Sci. 2016; 41:437–45.

30. Mazze RI, Kallén B. Reproductive outcome after anesthesia and operation during pregnancy: A registry study of 5405 cases. Am J Obstet Gynecol. 1989; 161:1178–85.

31. Singh O, Agrawal P, Garg R and Agarwal A. Drugs in Pregnancy: An Update. Journal of South Asian Federation of Obstetrics and Gynaecology 2014;6(3):7-11.

Cite This Article as: Amrit Mandal, Anwara Mammel, Harman Preet Kaur, Manav Deep Singh, Shreya Gujral, Anuj kumar. Glaucoma Management During Pregnancy and Lactation. Delhi Journal Ophthalmology 2020; 31 (3) : 9-12

Acknowledgments: Nil

Conflict of interest: None declared

Source of Funding: None

Date of Submission: 06 June 2020
Date of Acceptance: 13 August 2020

Address for correspondence

Harman Preet Kaur MBBS
Department of Gynaecology and Obstetrics, Palika Maternity Hospital, Lodhi Colony, New Delhi, India.
Email drharmanpreet@hotmail.com.